Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
GLP-1 agonists are FDA-approved drugs used to help lower blood sugar in people with type 2 diabetes
Nonsyndromic hearing impairment is associated with a mutation in DFNA5
#BMS #Cobenfy #Schizophrenia #Neuroscience #Psychiatry #PharmaNews #DrugDevelopment #Opdivo #Camzyos #AlzheimersDisease #Innovation #Healthcare #Biopharma To view or add a comment, sign in Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
As above, full details and formulas appear in Addition File 1
US$ 27.25
US$ 27.31
US$ 29.64
US$ 24.49
US$ 23.11
